In SS, there is dysregulation of IL-22 and aberrant expression of IL-22R1 on the surface of B and T cells [67], implying that they might act as a stimulatory pathway that can affect the self-perpetuation of the disease and perhaps explain why some SS patients progress to non-Hodgkin’s lymphoma (Table 1). The gene discussed is IL22RA1; the disease is synovial sarcoma.